Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Sustained-release implant promising for long-term IOP reduction
E. Randy Craven, MD, shares results from a phase 1/2 study involving an intracameral bimatoprost sustained-release implant.
E. Randy Craven, MD, discusses the pearls of his presentation, "Biodegradation of Intracameral Bimatoprost Sustained-Release Implant (Bimatoprost SR, Allergan) in a 24-Month, Phase 1/2 Study in Glaucoma Patients," which he shared at the annual 2019 ASCRS meeting in San Diego.
RELATED: Novel compound shows promise for dry eye in proof-of-concept study
Related Videos
Related Content
